Nusus Pharma (AMEX:NSRX) shares fell 5.02% at $2.65 at the time of publication on Wednesday, with the company's Phase 2 study results indicating that NS002 has the potential to exceed EpiPen performance. The study also revealed that the drug achieved a median time to the critical 100 pg/mL epinephrine threshold of 1.6 minutes, significantly faster than the widely used EpiP, demonstrating significant improvements in the time to therapeutic threshold. However, shares have decreased by 66.18% over the past 12 months and are currently closer to their 52-week lows than highs. Currently, the stock is trading 45.1% below its 20-day simple moving average (SMA) and 60.1%.